Thinh T Nguyen1, Hyun-Sung Lee2, Bryan M Burt2, Christopher I Amos1,3,4, Chao Cheng5,6,7. 1. Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030, USA. 2. Division of General Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, 77030, USA. 3. Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. 4. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. 5. Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 77030, USA. chao.cheng@bcm.edu. 6. Department of Medicine, Baylor College of Medicine, Houston, TX, 77030, USA. chao.cheng@bcm.edu. 7. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA. chao.cheng@bcm.edu.
Abstract
BACKGROUND: Malignant pleural mesothelioma (MPM) is a lung pleural cancer with very poor disease outcome. With limited curative MPM treatment available, it is vital to study prognostic biomarkers to categorise different patient risk groups. METHODS: We defined gene signatures to separately characterise intrinsic and extrinsic features, and investigated their interactions in MPM tumour samples. Specifically, we calculated gene signature scores to capture the downstream pathways of major mutated driver genes (BAP1, NF2, SETD2 and TP53) as tumour-intrinsic features. Similarly, we inferred the infiltration levels for major immune cells in the tumour microenvironment to characterise tumour-extrinsic features. Lastly, we integrated these features with clinical factors to predict prognosis in MPM. RESULTS: The gene signature scores were more prognostic than the corresponding genomic mutations, mRNA and protein expression. High immune infiltration levels were associated with prolonged survival. The integrative model indicated that tumour features provided independent prognostic values than clinical factors and were complementary with each other in survival prediction. CONCLUSIONS: By using an integrative model that combines intrinsic and extrinsic features, we can more correctly predict the clinical outcomes of patients with MPM.
BACKGROUND: Malignant pleural mesothelioma (MPM) is a lung pleural cancer with very poor disease outcome. With limited curative MPM treatment available, it is vital to study prognostic biomarkers to categorise different patient risk groups. METHODS: We defined gene signatures to separately characterise intrinsic and extrinsic features, and investigated their interactions in MPM tumour samples. Specifically, we calculated gene signature scores to capture the downstream pathways of major mutated driver genes (BAP1, NF2, SETD2 and TP53) as tumour-intrinsic features. Similarly, we inferred the infiltration levels for major immune cells in the tumour microenvironment to characterise tumour-extrinsic features. Lastly, we integrated these features with clinical factors to predict prognosis in MPM. RESULTS: The gene signature scores were more prognostic than the corresponding genomic mutations, mRNA and protein expression. High immune infiltration levels were associated with prolonged survival. The integrative model indicated that tumour features provided independent prognostic values than clinical factors and were complementary with each other in survival prediction. CONCLUSIONS: By using an integrative model that combines intrinsic and extrinsic features, we can more correctly predict the clinical outcomes of patients with MPM.
Authors: Lawrence A Donehower; Thierry Soussi; Anil Korkut; Yuexin Liu; Andre Schultz; Maria Cardenas; Xubin Li; Ozgun Babur; Teng-Kuei Hsu; Olivier Lichtarge; John N Weinstein; Rehan Akbani; David A Wheeler Journal: Cell Rep Date: 2019-07-30 Impact factor: 9.423
Authors: Raphael Bueno; Eric W Stawiski; Leonard D Goldstein; Steffen Durinck; Assunta De Rienzo; Zora Modrusan; Florian Gnad; Thong T Nguyen; Bijay S Jaiswal; Lucian R Chirieac; Daniele Sciaranghella; Nhien Dao; Corinne E Gustafson; Kiara J Munir; Jason A Hackney; Amitabha Chaudhuri; Ravi Gupta; Joseph Guillory; Karen Toy; Connie Ha; Ying-Jiun Chen; Jeremy Stinson; Subhra Chaudhuri; Na Zhang; Thomas D Wu; David J Sugarbaker; Frederic J de Sauvage; William G Richards; Somasekar Seshagiri Journal: Nat Genet Date: 2016-02-29 Impact factor: 38.330
Authors: Paul Markowitz; Malini Patel; Roman Groisberg; Joseph Aisner; Salma K Jabbour; Subhajyoti De; Shridar Ganesan; Jyoti Malhotra Journal: Cancer Treat Res Commun Date: 2020-11-03
Authors: Julija Hmeljak; Francisco Sanchez-Vega; Katherine A Hoadley; Juliann Shih; Chip Stewart; David Heiman; Patrick Tarpey; Ludmila Danilova; Esther Drill; Ewan A Gibb; Reanne Bowlby; Rupa Kanchi; Hatice U Osmanbeyoglu; Yoshitaka Sekido; Jumpei Takeshita; Yulia Newton; Kiley Graim; Manaswi Gupta; Carl M Gay; Lixia Diao; David L Gibbs; Vesteinn Thorsson; Lisa Iype; Havish Kantheti; David T Severson; Gloria Ravegnini; Patrice Desmeules; Achim A Jungbluth; William D Travis; Sanja Dacic; Lucian R Chirieac; Françoise Galateau-Sallé; Junya Fujimoto; Aliya N Husain; Henrique C Silveira; Valerie W Rusch; Robert C Rintoul; Harvey Pass; Hedy Kindler; Marjorie G Zauderer; David J Kwiatkowski; Raphael Bueno; Anne S Tsao; Jenette Creaney; Tara Lichtenberg; Kristen Leraas; Jay Bowen; Ina Felau; Jean Claude Zenklusen; Rehan Akbani; Andrew D Cherniack; Lauren A Byers; Michael S Noble; Jonathan A Fletcher; A Gordon Robertson; Ronglai Shen; Hiroyuki Aburatani; Bruce W Robinson; Peter Campbell; Marc Ladanyi Journal: Cancer Discov Date: 2018-10-15 Impact factor: 39.397
Authors: Anna C Bibby; Selina Tsim; Nikolaos Kanellakis; Hannah Ball; Denis C Talbot; Kevin G Blyth; Nick A Maskell; Ioannis Psallidas Journal: Eur Respir Rev Date: 2016-12
Authors: Brock C Christensen; John J Godleski; Cora R Roelofs; Jennifer L Longacker; Raphael Bueno; David J Sugarbaker; Carmen J Marsit; Heather H Nelson; Karl T Kelsey Journal: Environ Health Perspect Date: 2008-06 Impact factor: 9.031